45 results about "Uremia" patented technology

To provide a jelly composition containing spherical adsorptive carbon for improving uremic symptoms and delaying initiation of dialysis of chronic renal failure patients, which has more improved medication compliance than existing therapeutic agents.SOLUTION: The jelly composition contains spherical adsorptive carbon as an active ingredient, a gelling agent, a thickener, and spherical adsorptive carbon containing distilled water.SELECTED DRAWING: Figure 2

This invention relates to a dialysis apparatus which ultra-filters blood and to a related method of ultra-filtering blood ex-vivo.More preferably the invention relates to haemodiafiltration using protein-losing membranes and a secondary ultrafiltration and partial re-infusion of haemodiafiltrate for increasing extraction of middle molecules and protein bound uraemic toxins and reducing albumin loss.

The application belongs to the technical field of adsorbents, and provides a composite adsorbent material for uremia and a preparation method thereof, and the preparation steps are as follows: S1. Acrylamide, N,N'-methylenebisacrylamide, glycerol and deionized water are mixed, stirred, sodium alginate is added, stirred and dissolved, ammonium persulfate, calcium sulfate and tetramethylethylenediamine are sequentially added, stirred, ultrasonically treated, and heated and reacted to obtain a sodium alginate derivative; S2. The sodium alginate derivative and deionized water are mixed, modified high-density polyethylene is added, stirred, and soaked in a CaCl2 solution for crosslinking to obtain a sodium alginate composite material; S3. CeO2 / MoS2 functional material, sodium alginate and deionized water are mixed, the sodium alginate composite material is added and stirred, shaped, soaked in a CaCl2 solution for crosslinking, washed, and dried to obtain the composite adsorbent material. The composite adsorbent material has a high adsorption rate and high adsorption capacity for uremia toxins, and has good biocompatibility and hemocompatibility.

The application discloses a high-loading MXene-encapsulated magnetic porous microcapsule for adsorption and a preparation method and application thereof, and belongs to the field of biomedical materials, and the preparation method comprises the following steps: in step one, a hydrogel precursor solution doped with magnetic nanoparticles is used as an external phase, and a MXene dispersion liquid is used as an inner phase, and a microfluidic coaxial electrospraying device is used to generate monodisperse core-shell droplets with uniform sizes; in step two, the monodisperse core-shell droplets prepared in step one are subjected to freezing pretreatment, and then are crosslinked with divalent metal ions, so that double gelation of the core layer and the shell layer is triggered, and hydrogel microspheres with a core-shell structure are obtained; and in step three, the hydrogel microspheres with the core-shell structure obtained in step two are subjected to freeze drying, and high-loading MXene-encapsulated magnetic porous microcapsules are obtained. The application has excellent blood compatibility and high adsorption capacity, and is outstanding in removing uremic toxins including creatinine, urea and uric acid, and is a kind of adsorbent which is both efficient and safe.

The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

The present disclosure relates to RNAi agents able to inhibit Complement Factor B (CFB) gene expression. Also disclosed are pharmaceutical compositions that include CFB RNAi agents and methods of use thereof. The CFB RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the in vivo delivery to hepatocyte cells. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), Anti-Glomerular Basement Membrane disease (anti-GBM), ischemia reperfusion injury and T-cell mediated rejection (TCMR) in kidney transplantation, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD), including early and / or intermediate AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated diseases.

The invention provides a preparation process and a use method of a medicinal and edible substance composition. The medicine overcomes the defects that rejection reaction is insufficient when cancer is treated by a stem cell transplantation method and organ lesions cannot be treated simultaneously when cancer is treated by an immune cell method and a vaccine cell method; the oral liquid comprises the following raw materials in parts by weight: 0.1-3.0 parts of cordyceps militaris, 0.1-3.0 parts of fermented cordyceps sinensis powder, 1.0-3.5 parts of pseudo-ginseng, 1.0-2.5 parts of American ginseng, 1.0-1.5 parts of salvia miltiorrhiza powder or ligusticum wallichii, 1.0-3.0 parts of high-quality gastrodia elata and medicinal pure honey which is 0.9-1.3 times of the total weight of the medicinal materials. The preparation method comprises the following steps: mixing prescription raw materials, crushing, adding honey, and preparing honeyed boluses or beverages. The medicine disclosed by the invention is safe, can treat cancers, diabetes mellitus, heart diseases, liver diseases, nephropathy, uremia or entanglement of a plurality of diseases with high curative effect, and enables patients to be young; according to the invention, messy code genes of a patient can be normally edited while the disease is treated.

Metal-organic framework molecules with pyrene group-containing or biphenyl group-containing linkers for use in the removal of uremic toxins from biological samples that contain such toxins are provided. Also provided are methods for using the MOFs to remove uremic toxins from biological samples. The methods include hemodialysis of blood samples from patients suffering from a uremia-related disease, such as chronic kidney failure.

Metal-organic framework molecules with pyrene group-containing or biphenyl group-containing linkers for use in the removal of uremic toxins from biological samples that contain such toxins are provided. Also provided are methods for using the MOFs to remove uremic toxins from biological samples. The methods include hemodialysis of blood samples from patients suffering from a uremia-related disease, such as chronicap kidney failure.

The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

The application discloses a quantitative-discriminative integrated uremia intelligent detection system, and relates to the field of medical spectrum analysis.The system comprises a spectrum collection module, which is used for collecting near-infrared transmission spectrum data of a serum sample to be measured; and a double-model detection module, which is used for determining urea concentration and a uremia state of the serum sample to be measured by using a pre-constructed urea concentration quantitative regression model and a uremia state discriminative classification model respectively according to the near-infrared transmission spectrum data.The application realizes accurate determination of urea concentration and rapid automatic identification of uremia, and has significant advantages in reducing cost, simplifying process and improving diagnosis efficiency.

The present invention relates to the field of biomedicine technology, and proposes a heparin-capturing uremic toxin adsorbent and a preparation method thereof. The raw materials of the adsorbent include styrene, acrylic acid, and divinylbenzene. Through the above technical solution, using polystyrene as the basic skeleton, by introducing polar monomers into the main structure, and activating the introduction of active groups such as hydroxyl and chloromethyl groups on the skeleton surface, a heparin-capturing adsorbent is prepared that can be rapidly cross-linked with heparin surface active groups through physical and chemical reactions to form an anti-coagulant surface. This solves the problem in the prior art that uremic toxin adsorbents can cause coagulation complications when used clinically.

The described technology can include methods of treating a population of red blood cells (RBCs) in an individual, particularly a chronic kidney disease (CKD) patient with renal anemia, by reducing the amount of a Piezo1 chemical agonist in the patient's blood. In one embodiment, a method of treating a patient with renal anemia can include increasing RBC lifespan of a population of RBCs in the patient by reducing Piezo1 channel activation duration of at least a portion of the population of RBCs by reducing the amount of a target uremic compound in the patient's blood, the target uremic compound having a form that prolongs Piezo1 channel activation duration, wherein the amount of the target uremic compound can be reduced by selectively removing at least a portion of the target uremic compound from the patient's blood. Other embodiments are also described.

The present invention provides a double-layer hollow fiber membrane for enclosing a hollow space through which blood flows and transporting uremic toxins and waste products from the blood to the outside, and a method for manufacturing the same. The double-layer hollow fiber membrane includes a first layer having first pores and a second layer having second pores. The first pores of the first layer and the second pores of the second layer are connected to each other, and the second pores are open pores connected to the outside. The double-layer hollow fiber membrane can remove uremic toxins with molecular sizes from blood while minimizing the loss of blood components and essential proteins due to the pores increasing in size from the first pores to the second pores.

The invention discloses resin with super-strong adsorption performance as well as a preparation method and application thereof. Macroporous adsorption resin is prepared from a polyvinyl cross-linking agent and a pore-foaming agent, and then a polymer is grafted through residual hanging double bonds. The macroporous adsorption resin prepared by using the method has a huge specific surface area and abundant pore channels, and has super-strong adsorption performance on macromolecular toxins such as parathyroid hormone and beta2-microglobulin in the body of a uremia patient, and in addition, hydroxyethyl polymethacrylate is grafted on the surface of the resin, so that the hemolysis rate is reduced, and the blood compatibility is improved.

The present disclosure relates to stable aqueous solutions comprising high concentrations of an anti-C5 antibody (e.g., ravulizumab) and methods of making the solutions. The present disclosure also provides methods of using the solutions to treat or prevent complement-associated disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Therapeutic kits containing one or more of the solutions, and means for administering the solutions to a patient in need of such treatment, are also contemplated.

The invention belongs to the technical field of Chinese herbal medicines, and particularly relates to a traditional Chinese medicine herbal composition for preventing and treating diabetic complications and a preparation method thereof. The traditional Chinese medicine herbal composition is prepared from folium mori, radix astragali, radix rehmanniae, radix polygonati officinalis, radix ophiopogonis, rhizoma dioscoreae, poria cocos, radix puerariae, opuntia ficus-indica, inulin, rumex hanus, American ginseng and rhizoma curcumae longae. The traditional Chinese medicinal materials are combined to clean sugar scale micro-crystals in blood vessel microcirculation, improve the functions of liver and pancreas islet, regulate the blood sugar level and enhance the anti-oxidation and self-healing capability of a body, so that the blood sugar is stabilized; the occurrence of diabetic complications such as fundus retinopathy, neuropathy, hypertension, cerebral infarction, myocardial infarction, uremia and gangrene is prevented and controlled. Besides, the traditional Chinese medicine composition is a pure herbal traditional Chinese medicine formula, is high in safety and exact in curative effect, and has a wide application prospect in the field of prevention and treatment of diabetic complications.

The present invention relates to antibodies or antigen-binding fragments thereof, specific for a uremic toxin(s), compositions comprising these antibodies or antigen-binding fragments, and methods of use thereof.

The invention relates to resistant starch, a recombination method and application of the resistant starch in nephropathy treatment, the resistant starch comprises oat, brown rice, raw potatoes, black beans, red beans, mung beans and retrogradation starch, the resistant starch is recombined by adopting extrusion puffing, microwave-enzyme synergistic recombination and pressure heating-freezing and thawing cycle recombination methods, and the resistant starch can be applied to prevention and / or treatment of diabetic nephropathy. And the recombinant resistant starch is not digested in small intestines and is fermented by intestinal flora to generate SCFA (Small Form Fatty Acid) such as butyric acid and propionic acid after reaching colon, so that the proliferation of bifidobacteria and lactic acid bacteria is promoted, and urease-producing bacteria are inhibited. The resistant starch can reduce generation of intestinal uremia toxins in vivo, reduce the situation that the intestinal uremia toxins enter blood circulation through intestinal-renal axes, and relieve oxidative stress and fibrosis of renal tubules. The SCFA promotes the secretion of GLP-1, improves the insulin sensitivity and reduces the damage of hyperglycemia to the kidney.

The application provides a traditional Chinese medicine composition for treating uremia and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition for treating uremia is prepared from raw materials and is characterized by kidney-tonifying, spleen-strengthening, qi-benefiting, turbidity-removing, dampness-removing and blood-stasis-removing, and is an effective medicine for treating chronic renal failure and is worth popularization and application.

The application belongs to the technical field of traditional Chinese medicines, and relates to a uremia clearing tablet and a preparation method thereof. The uremia clearing tablet comprises the following raw materials in parts by mass: 40 parts of rhubarb, 36 parts of licorice, 160 parts of astragalus, 120 parts of mulberry bark, 80 parts of sophora, 120 parts of codonopsis, 200 parts of atractylodes, 200 parts of poria, 120 parts of white peony root, 1000 parts of chrysanthemum, 200 parts of prepared rehmannia, 120 parts of chuanxiong, 200 parts of salvia, 80 parts of pinellia, 200 parts of plantain, 60 parts of bupleurum, 400-600 parts of pregelatinized starch, 100-200 parts of hydroxypropyl-beta-cyclodextrin, 80-150 parts of co-processed material, 70-100 parts of low-substituted hydroxypropyl cellulose, 10-15 parts of anhydrous calcium hydrogen phosphate, 5-8 parts of fumaric acid and 22-32 parts of lubricant. The uremia clearing tablet provided by the application has good formability, short disintegration time and good stability without coating.

The invention belongs to the technical field of adsorbents, and provides a composite adsorption material for uremia and a preparation method of the composite adsorption material for uremia. The preparation method comprises the following steps: mixing N, N '-methylene bisacrylamide, glycerol and deionized water, stirring, adding sodium alginate, stirring for dissolving, sequentially adding ammonium persulfate, calcium sulfate and tetramethylethylenediamine, stirring, performing ultrasonic treatment, and heating for reaction to obtain a sodium alginate derivative; s2, mixing a sodium alginate derivative and deionized water, adding modified high-density polyethylene, stirring, and soaking in a CaCl2 solution for crosslinking to obtain a sodium alginate composite material; s3, mixing the CeO2 / MoS2 functional material, sodium alginate and deionized water, adding the sodium alginate composite material, stirring, forming, soaking in a CaCl2 solution for crosslinking, washing and drying to obtain the composite adsorption material. The composite adsorption material disclosed by the invention is high in adsorption rate and high in adsorption capacity on uremia toxins, and has relatively good biocompatibility and blood compatibility.

The invention discloses a traditional Chinese medicine compound preparation for treating nephrotic syndrome and a preparation method of the traditional Chinese medicine compound preparation, and belongs to the technical field of nephrotic syndrome treatment.The synbiotic microcapsule is prepared by compatibility of traditional Chinese medicines such as safflower, scutellaria baicalensis and perilla frutescens, and the synbiotic microcapsule is prepared by embedding traditional Chinese medicine extracts such as astragalus membranaceus and lily with lactobacillus acidophilus and bifidobacterium; and the wall material is prepared from mannose grafted meadowfoam seed extract, sodium alginate and fucoidin sulfate. The synbiotics microcapsule utilizes a Maillard reaction modified wall material to enhance gastric acid erosion resistance, realizes intestinal targeted colonization through mannose residues, protects probiotics, directionally releases traditional Chinese medicine active components, adjusts intestinal flora balance and inhibits uremia toxin generation. The traditional Chinese medicine components such as the safflower and the scutellaria baicalensis improve kidney blood circulation, relieve inflammatory response and regulate lipid metabolism by inhibiting an NF-kappa B channel, activating an AMPK channel and the like; the components such as the Chinese yam and the Chinese wolfberry can repair the permeability of glomerular basement membrane and improve the hypoproteinemia.

The invention discloses a traditional Chinese medicine formula for preventing and treating diabetic nephropathy. The important composition is prepared from the following raw material medicines: 100g of gynura divaricata, 100g of silybum marianum seeds, 100g of clerodendranthus spicatus, 60g of melastoma dodecandrum, 60g of horseradish tree leaves, 60g of sappan wood, 60g of pseudo-ginseng, 60g of ligusticum chuanxiong hort, 60g of leech, 60g of gardenia jasminoides, 60g of sweet potato pulp, 60g of centella asiatica and 60g of cottonrose hibiscus leaves. The traditional Chinese medicine composition is prepared into pills and granules, is a pure traditional Chinese medicine preparation, and has a special effect on treating the diabetic complication kidney. The traditional Chinese medicine composition can effectively inhibit and degrade blood muscle liver, urea nitrogen and blood toxins, can gradually restore the renal function of some mild and moderate diabetic nephropathy patients to normal, and can replace hemodialysis or reduce the number of dialysis times for some severe uremia patients.

The embodiment of the invention provides a cerebral apoplexy risk prediction system applied to uremia patients and a computer device, and the cerebral apoplexy risk prediction system comprises an acquisition unit which is used for respectively acquiring basic physiological index data, first real-time physiological data, dialysis effect data and a second real-time physiological data set; the first prediction unit is used for predicting a first cerebral apoplexy occurrence risk value in the dialysis process through a first prediction model; the second prediction unit is input into a second prediction model to predict and obtain a second cerebral apoplexy occurrence risk value; and the switching unit responds to a switching signal representing entering or exiting of the dialysis process to correspondingly switch and use the first prediction unit or the second prediction unit. Different prediction models are adopted in stages, the cerebral apoplexy risk is predicted according to different physiological data changes of uremia patients in the dialysis process and after dialysis is finished, and then the timeliness and accuracy of risk prediction are improved.

The American ginseng and mesona chinensis preparation is prepared from 6-60 parts of American ginseng powder, 5-50 parts of mesona chinensis (mesona chinensis) powder, 5-50 parts of lucid ganoderma powder, 4-40 parts of gastrodia elata powder, 4-40 parts of astragalus membranaceus powder, 4-40 parts of rhizoma polygonati powder, 3-30 parts of folium cortex eucommiae powder, 2-20 parts of cistanche deserticola powder, 2-20 parts of codonopsis pilosula powder, 1-10 parts of lophatherum gracile powder, 1-10 parts of poria cocos powder, 1-10 parts of herba cepbalanoplosis segeti powder and 1-10 parts of gordon euryale seed powder. The traditional Chinese medicine can clear away heat and toxic materials, induce diuresis to alleviate edema, improve human immunity, effectively reduce creatinine, uric acid, blood pressure and blood sugar, and has good treatment effects on uremia, nephritis, renal cyst, kidney stone, hepatitis B, cirrhosis, liver ascites, insomnia, asthma, pharyngitis, cough, cancerous diseases and cardia-cerebrovascular diseases.

A method of performing dialysis includes: recirculating a dialysis fluid from a patient or a dialyzer for at least two cycles, each cycle contacting the dialysis fluid first with a zirconium phosphate layer followed by at least one of a urease layer, a zirconium oxide layer, or a carbon layer; storing the recirculated dialysis fluid in a storage container; and transferring the dialysis fluid from the storage container to the patient or the dialyzer. In one example, the zirconium phosphate layer and the at least one of the urease layer, the zirconium oxide layer, or the carbon layer is provided by a sorbent cartridge.

The present disclosure is directed to hemodialysis membranes. In particular, the present disclosure relates to hemodialysis membranes comprising uremic metabolites and zwitterionic moieties, and methods of hemodialysis thereof.

The present invention relates to a new process for the preparation of heterocyclic derivative compounds of Formula I; to new intermediate compounds used in said process for the preparation; to compositions for the treatment or prevention of hyperuricemia, gout disease, nephritis, chronic renal failure, kidney stones, uremia, urinary stones or uric acid-related diseases, said compositions comprising a compound of Formula I at a dosage of administration of more than 2 mg to 10 mg below, administered orally once a day; and to new hydrochloride 1.5 hydrate salts of compounds of Formula I.